The company depends on third parties for key products, services, and licenses related to technology and intellectual property rights. These suppliers may increase costs, limit usage, or deny licensing, which could restrict access to essential data or services and adversely impact the company's operating results and financial condition. Failure by third parties to deliver required products, services, or licenses could disrupt operations. The company operates in a highly competitive and dynamic market, where outsourcing trends and consolidation among large pharmaceutical companies may influence its growth and operating results.
Icon Plc's Comment on Supply Chain
The company depends on third parties for key products, services, and licenses related to technology and intellectual property rights. These suppliers may increase costs, limit usage, or deny licensing, which could restrict access to essential data or services and adversely impact the company's operating results and financial condition. Failure by third parties to deliver required products, services, or licenses could disrupt operations. The company operates in a highly competitive and dynamic market, where outsourcing trends and consolidation among large pharmaceutical companies may influence its growth and operating results.
Sources:
Icon Plc's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Icon Plc’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
